From the annual meeting of the American Society of Clinical Oncology in Orlando, Fla.
This is my third year covering the annual ASCO meeting. It’s still overwhelming and adrenaline-producing with more than 30,000 attendees from around the world.
But I’m also starting to feel a part of it. I’ve followed some of the same studies every year, watching a small part of a specific type of cancer become better understood or witnessing better and longer responses with some very innovative therapies. For example, one of the first stories that I covered at ASCO was an investigational vaccine for glioblastoma multiforme aimed at epidermal growth factor receptor variant III (EGFRvIII) . Today I caught up on the latest results and the immune response is still looking impressive (abstract 2021).
It made me realize that we all—patients, researchers, physicians, nurses, other health professionals, and even medical writers—have an important part to play in fighting cancer.
—Kerri Wachter (follow me at ASCO on Twitter @knwachter, #ASCO)